Metraipolis › archive › dc_9746ce568702

Evaluating Ki-67 and PR as prognostic indicators in CDK4/6 inhibitor treatment for metastatic breast cancer — Europe PMC PMID:41333370

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41333370
DOI
10.3332/ecancer.2025.1963
License (as archived)
solo-consultazione
Archived
2026-11-10T16:51:42.648Z
SHA-256 of the archived text
afc9aab9cdb84b26781462258e6bbf67bce572717ad2df3d2aa0c12390307616
Stable URL of this page
https://metraipolis.com/documento/dc_9746ce568702

How to cite

Evaluating Ki-67 and PR as prognostic indicators in CDK4/6 inhibitor treatment for metastatic breast cancer — Europe PMC PMID:41333370 — Europe PMC (en), https://europepmc.org/article/MED/41333370 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9746ce568702 (Metraipolis archive dc_9746ce568702, sha256 afc9aab9cdb84b26781462258e6bbf67bce572717ad2df3d2aa0c12390307616)
BibTeX
@misc{dc9746ce568702,
  title = {Evaluating Ki-67 and PR as prognostic indicators in CDK4/6 inhibitor treatment for metastatic breast cancer — Europe PMC PMID:41333370},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41333370},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9746ce568702; sha256 afc9aab9cdb84b26781462258e6bbf67bce572717ad2df3d2aa0c12390307616},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41333370. Agents can read the archived copy with the MCP tool read_document.